Noticias y Eventos

Descubra las novedades en el campo de las patologías oculares hereditarias

Blog operado por el equipo de DBGen que actualiza terapias, noticias y eventos relacionados con las enfermedades hereditarias oculares. Le invitamos a participar en este foro.

Filters

Category list

Leber Congenital Amaurosis DBGen Macular degeneration Genetic Diagnosis Retinal Dystrophy Gene editing Research Mutation Patients Stargardt Therapy Gene Therapy

Entry date

January 2020 (1)

December 2019 (2)

November 2019 (1)

October 2019 (2)

September 2019 (1)

August 2019 (2)

July 2019 (1)

June 2019 (2)

May 2019 (1)

April 2019 (2)

March 2019 (2)

February 2019 (1)

January 2019 (1)

December 2018 (2)

October 2018 (2)

September 2018 (1)

July 2018 (2)

May 2018 (2)

April 2018 (3)

March 2018 (2)

February 2018 (3)

January 2018 (2)

December 2017 (1)

Subscribe to our blog

Gene therapies open very promising scenarios for the treatment of genetic blindness

23/09/19 - Retinal Dystrophy, Gene Therapy,

Not so far ago, a patient that was clinically diagnosed with a retinal inherited dystrophy had to face an unavoidable outcome, eventual blindness. No effective treatment to cure or halt the progression of the disease was available. This gloomy perspective has been completely upturned by the implementation of cutting edge technologies, and the future looks promising for patients and their...

New RNA therapy for autosomal dominant retinitis pigmentosa

27/08/19 - Retinal Dystrophy, Gene Therapy,

The United States Food and Drug Administration (FDA) has just approved the designation of the QR-1123 therapy by the Dutch company ProQR as a new investigational drug. This drug aims to treat a form of autosomal dominant retinitis pigmentosa (RPad) caused by the P23H mutation in the rhodopsin gene (RHO). QR-1123 is an antisense oligonucleotide, that is, a short RNA...

A race against the clock for Leber congenital amaurosis gene therapy

14/08/19 - Leber Congenital Amaurosis, Retinal Dystrophy, Gene Therapy,

ProQR Sepofarsen therapy On July 29, the Dutch company ProQR announced that the European Medicines Agency (EMA) has granted access to the Agency's priority medicine program (PRIME) to its Sepofarsen therapy (QR-110), designed for the treatment of Leber congenital amaurosis (LCA10), a childhood blinding disorder, caused by the c.2991+1655A>G (p.Cys998 *) mutation in the CEP290 gene. The EMA PRIME program...

DBGen and the UB-CIBERER U-718 group present their current research in genetic diagnosis and animal models of inherited retinal dystrophies in ARVO 2019

13/05/19 - DBGen, Genetic Diagnosis, Retinal Dystrophy, Research, Gene Therapy,

Dr. Gemma Marfany (co-founder and scientific board member of DBGen) presented an oral communication in ARVO 2019 (held in Vancouver, 2-6 May) to show the most prominent results of the research that his group at the UB-CIBERER (U-718) and DBGEN are currently undertaking to study inherited retinal dystrophies. This work is focused on improved genetic diagnosis and the generation of...

RPGeNet v2.0 allows visualizing interactions of more than 270 causative genes of inherited retinal dystrophies

30/04/19 - Retinal Dystrophy, Research,

RPGeNet is a network dedicated to provide a graphical platform that links retinal dystrophies causative genes with their molecular interactors. The aim of this network is granting researchers a tool that allows them to understand the pathological process in its cellular and histological context, highlight key molecular players of retinal degeneration and unveil new candidate genes of these diseases (Boloc...

First patient treated in ProQR STELLAR phase 1/2 gene therapy clinical trial for Usher Syndrome Type II

13/03/19 - Retinal Dystrophy, Research, Gene Therapy,

Usher syndrome is a genetic disorder that presents recessive inheritance and is characterized by hearing loss and retinitis pigmentosa, traits that may be total or partial. The prevalence of this disease is 1: 30,000 individuals considering the three types of USHER identified, the most common being type II (60% of cases), caused mostly by the USH2A gene. There was no...

1 2 3 >